Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy for the Treatment of HIV-1 in Adults New to HIV Therapy. The data were presented during a late-breaking abstract session at the 2018 HIV Glasgow conference in Glasgow, Scotland, UK.

Gilead Sciences, Inc. today announced 96-week results from a Phase 3, randomized, double-blinded study evaluating the safety and efficacy of Biktarvy. for the treatment of HIV-1 infection in treatment-naïve adults. In the ongoing study, Biktarvy was found to be statistically non-inferior to a regimen of dolutegravir and emtricitabine/tenofovir alafenamide (50 mg) through 96 weeks of therapy.

“This study demonstrated the high efficacy, high barrier to resistance and long-term tolerability profile of Biktarvy through 96 weeks, reaffirming its role as a first-line treatment option for appropriate adult HIV patients who are starting therapy,” said Hans-Jürgen Stellbrink, MD, PhD, Professor of Internal Medicine, Infectious Diseases, at the University of Hamburg, Germany and lead study author.

https://spid.center/en/

This post has been edited by JusticeFry: Nov 2 2018, 02:24 AM